New York (AP) – The pharmaceutical company Pfizer has had to halve the delivery target for its corona vaccine this year, among other things due to delays in expanding the supply chain. The expansion is taking longer than expected, a company spokeswoman told the Wall Street Journal on Thursday. In addition, the results of the clinical study were available later than originally thought.
According to the newspaper, Pfizer held internally until mid-November to deliver 100 million vaccine doses by the end of this year. Most recently, however, the company spoke of 50 million cans. For the coming year, the original plan to deliver more than a billion vaccine doses will remain, the newspaper continued.
Those who get vaccinated need two doses to be protected. Pfizer developed the vaccine together with the German manufacturer Biontech from Mainz.
The report said, citing a person involved in vaccine development, that some components did not meet standards in early production. The group initially did not respond to a request for further information.
The British Medicines Agency granted Pfizer and Biontech emergency approval for their corona vaccine on Wednesday. The UK is the first country to issue a clearance certificate for the vaccine. The US Food and Drug Administration and the European Medicines Agency Ema are currently examining such applications.
– .
